European Monitoring Centre for Drugs and Drug Addiction. (2018) Report on the risk assessment of methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances. Luxembourg: Publications Office of the European Union.
| Preview | Title | Contact |
|---|---|---|
|
PDF (Risk assessment carfentanil)
- Published Version
1MB |
This publication presents the data and findings of the risk assessment on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place carfentanil in Schedule I and Schedule IV of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.
Carfentanil or carfentanyl is an analog of the synthetic opioid analgesic fentanyl.
E Concepts in biomedical areas > Pharmacology and toxicology
J Health care, prevention, harm reduction and treatment > Risk and needs assessment > Risk assessment
L Social psychology and related concepts > Legal availability or accessibility
VA Geographic area > International
Repository Staff Only: item control page